Piper Sandler raised the firm’s price target on Guardant Health (GH) to $60 from $50 and keeps an Overweight rating on the shares. The firm updated the company’s model post the earnings report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $57 from $52 at Scotiabank
- Cathie Wood Loses Confidence in Palantir Stock (PLTR) Ahead of Q1 Earnings
- Guardant Health Reports Strong Q1 Revenue Growth
- Cathie Wood’s ARK Investment buys 186.8K shares of Guardant Health today
- Guardant Health price target raised to $60 from $56 at TD Cowen